Immunovant, Inc. (IMVT) Cash Flow Statement

The OCF/NI ratio has remained below 1.0 in most quarters, suggesting that non-cash charges like stock-based compensation are not fully offsetting working capital outflows. In 2027Q1, SBC of $13.8M was more than offset by a $14.9M working capital source, yet OCF still lagged net income, implying other accrual adjustments are consuming cash. This pattern indicates that reported losses may understate the true cash drain, warranting close monitoring of accrual quality.

The FCF trajectory shows a clear acceleration in cash consumption, with quarterly burn more than doubling over the period. Despite the first revenue of $7.1M in 2027Q1, FCF margin remains deeply negative at -17.5%, indicating that commercial revenue is immaterial relative to operating costs. This suggests the company is in a heavy investment phase, and investors should expect continued cash burn until clinical milestones translate into meaningful sales.

The near-zero capex suggests that Immunovant's cash burn is driven almost entirely by operating expenses, particularly R&D, rather than investment in fixed assets. This is typical for a biotech with outsourced manufacturing, but it also means that the company's cash needs are directly tied to its clinical pipeline. As the company scales commercial operations, capex may rise, but currently it does not represent a meaningful cash outflow.

The working capital line has been a source of cash in several quarters, including a large $41.5M inflow in 2026Q4, which helped moderate cash burn. However, these swings are likely due to timing of payables and accruals, not sustainable improvements in cash conversion. The negative working capital changes in other quarters indicate that the company is not consistently managing its working capital to reduce cash needs, and investors should not rely on these fluctuations to offset operating losses.

The absence of capital returns is consistent with a development-stage biotech conserving cash for clinical programs. The company's cash deployment is entirely focused on advancing its pipeline, which is reflected in the escalating R&D expenses. This strategy may be appropriate given the potential upside, but it also means that shareholders are relying solely on future value creation, with no current return on investment.

The cumulative gap of roughly $180M between net income and operating cash flow suggests that non-cash charges, primarily stock-based compensation, are significant. This implies that while the company is burning cash heavily, the economic cost to shareholders is partially non-cash, which may be dilutive rather than depleting cash reserves. However, the trend is concerning as the gap narrows in recent quarters, indicating that cash burn is catching up to reported losses, which could pressure liquidity if the company cannot raise additional capital.